Cardiome Pharma Corp. (CRME)

All Comments on CRME

  • commenter
    StockMarketF
    unding
    Aug 12 12:59 AM
    My Website
    Monday Options Outlook: AMZN, MCD, EL, CRME, VRX, CCK, CNO [view article]
    I think this move in AMZN is due to the August light volume moves we always see and I suggest people consider hedging any profits. Reply
  • commenter
    ksmithdc
    Jul 24 09:37 AM
    My Website
    eBay is a Not Com - Cramer's Lightning Round (7/23/08) [view article]
    As a healthcare provider, I can tell you that United Health Care is a joke. They are continuously rated as the worst healthcare plan in the country. May they go bankrupt and soon. Reply
  • commenter
    Pelion
    Jul 16 11:24 AM
    Cardiome Pharma: More Encouraging Trial Results [view article]
    >Cardiome USA is still awaiting FDA action on Kynapid however
    >(almost six months overdue), and we are unsure if this could >preclude a deal in the near-term.

    The IV program has a US partner with Astrellas. It has no bearing on seeking an oral partner which is a distinct program addressing a much bigger market.     Reply
  • commenter
    who noze
    May 23 06:13 AM
    Six Canadian Life Sciences Stocks [view article]
    good spec @1 p.s. they are also in oral diabetic insulin GNBT Reply
  • commenter
    R J Steffens
    May 22 12:59 AM
    Six Canadian Life Sciences Stocks [view article]
    Hi Stockerblog. That is an interesting article on Canadian Life Science companies with market caps above $250 million. But what about promising Life Science companies that have caps under $250 million? Often, with risk, that is where the largest gains may be found. Aplace to look for promise is at the upcoming ASCO 2008 presentations,and the abstracts are no longer under embargo.

    Looks like this one of a Phase I study I found from ASCO 2008 is not only safe (no grade 3 toxicity cases), but is the first peptide vaccine to exhibit such positive immuno responses even WITHOUT an adjuvant:

    Results of the first phase I clinical trial of the novel Ii-key hybrid preventive HER2/neu peptide (AE37) vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03.
    Sub-category: Vaccines
    Category: Developmental Therapeutics: Immunotherapy
    Meeting: 2008 ASCO Annual Meeting

    "Results: All 15 patients completed the trial with no grade 3-5 local or systemic toxicities. Dose reductions occurred in 47% of patients for local reactions >100mm or grade 2 systemic toxicities. The second group (peptide=500mcg, GM-CSF=250mcg) all required dose reductions prompting peptide-only inoculations in the third group (peptide=1,000mcg, GM-CSF=0mcg). AE37, with and without GM-CSF, elicited dose-dependent immunologic responses in vitro and in vivo to both AE37 and AE36 albeit AE37 responses were more robust. Assessing both toxicities and immunologic responses, the hypothesized optimal biologic dose was determined as peptide=500mcg, GM-CSF=62.5mcg, in 6 monthly injections. Conclusions: The hybrid AE37 vaccine appears safe and well tolerated with minimal local or systemic toxicity if properly dosed. AE37 is capable of eliciting HER2/neu-specific immune responses, even without the use of an adjuvant.

    This trial represents the first human experience with the Ii-Key modification, and to our knowledge, AE37 is the first peptide-based cancer vaccine to show potency in the absence of an immunoadjuvant."

    abstract.asco.org/Abst...

    AE37 vaccine is from Antigen Express- a wholly owned subsidary of (GNBT) Generex from Ontario. This is now in a large Phase II with the USMCI. What do you think, eh? ;)
    Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:19 AM
    My Website
    General Discussion on CRME
    Is this a buy or a sell? Reply
  • commenter
    Giorgio
    Ferrero
    Mar 20 11:13 AM
    Under The Radar News - Thursday [view article]
    I always enjoy reading articles from Seeking Alpha.

    Thank you for this timely information Mr. Hoffman     Reply
Loading...
Symbols:
Authors:
Quick Links: